Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma

Clinical Neuropathology

Volumn 33, Issue 1, 2014, Pages 6-14

  Preusser, Matthias ^a   Berghoff, Anna S ^a   Manzl, Claudia ^b   Filipits, Martin ^a   Weinhäusel, Andreas ^c   Pulverer, Walter ^c   Dieckmann, Karin ^a   Widhalm, Georg ^a   Wöhrer, Adelheid ^a,d   Knosp, Engelbert ^a   Marosi, Christine ^a   Hainfellner, Johannes A ^a,d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c AIT AUSTRIAN INSTITUTE OF TECHNOLOGY   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Glioblastoma; Methylation; MGMT; Predictive; Prognostic

Indexed keywords

BISULFITE; DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; DNA ISOLATION; GLIOBLASTOMA; HUMAN; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN METHYLATION; PYROSEQUENCING; QUALITY CONTROL;

ADULT; AGED; BRAIN NEOPLASMS; DIPHOSPHATES; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GLIOBLASTOMA; HUMANS; LUMINESCENT MEASUREMENTS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS, GENETIC; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, DNA; SULFITES; TUMOR SUPPRESSOR PROTEINS;

EID: 84891648431     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/NP300730     Document Type: Article

References (28)

1. Preusser M, de Ribaupierre S, Wöhrer A, Erridge SC, Hegi M, Weller M, Stupp R. Current concepts and management of glioblastoma. Ann Neurol. 2011; 70: 9-21. CrossRef PubMed
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10: 459-466. CrossRef PubMed
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, MirimanoffROEuropean Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996. Cross- Ref PubMed
4. Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma - are we there yet? Neuro-oncol. 2013; 15: 4-27. CrossRef PubMed
5. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008; 62: 753-764., discussion 264-266. Cross- Ref PubMed
6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, MirimanoffRO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997-1003. CrossRef PubMed
7. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M; NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012; 13: 707-715. CrossRef PubMed
8. Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R; Nordic Clinical Brain Tumour Study Group (NCBTSG). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012; 13: 916-926. CrossRef PubMed
9. Preusser M, Elezi L, Hainfellner JA. Reliability and reproducibility of PCR-based testing of O6-methylguanine- DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. Clin Neuropathol. 2008; 27: 388-390. CrossRef PubMed
10. BerghoffAS, Preusser M. Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients - yes, but how? Clin Neuropathol. 2012; 31: 405-408. CrossRef PubMed
11. Mikeska T, Bock C, El-Maarri O, Hübner A, Ehrentraut D, Schramm J, Felsberg J, Kahl P, Büttner R, Pietsch T, Waha A. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn. 2007; 9: 368-381. CrossRef PubMed
12. Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, Schackert G, Kreth FW, Pietsch T, Löffler M, Weller M, Reifenberger G, Tonn JC; German Glioma Network. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer. 2011; 129: 659-670. CrossRef PubMed
13. Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussière M, Lesimple T, Chinot O, Wager M, Honnorat J, Saikali S, Fina F, Sanson M, Figarella-Branger D. Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine- DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer. 2012; 118: 4201-4211. CrossRef PubMed
14. Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, Saikali S, Etcheverry A, Hamlat A, Loussouarn D, Campion L, Campone M, Vallette FM, Gratas-Rabbia-Ré C. Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol. 2010; 97: 311-322. CrossRef PubMed
15. Christians A, Hartmann C, Benner A, Meyer J, von Deimling A, Weller M, Wick W, Weiler M. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS ONE. 2012; 7: e33449. CrossRef PubMed
16. Håvik AB, Brandal P, Honne H, Dahlback HS, Scheie D, Hektoen M, Meling TR, Helseth E, Heim S, Lothe RA, Lind GE. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Transl Med. 2012; 10: 36. CrossRef PubMed
17. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, Crooks D, Husband D, Shenoy A, Brodbelt A, Wong H, Liloglou T, Haylock B, Walker C. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer. 2009; 101: 124-131. CrossRef PubMed
18. Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, Westphal M, Wick W, Pietsch T, Loeffler M, Weller M; German Glioma Network. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer. 2012; 131: 1342-1350. CrossRef PubMed
19. Preusser M, Plumer S, Dirnberger E, Hainfellner JA, Mannhalter C. Fixation of brain tumor biopsy specimens with RCL2 results in well-preserved histomorphology, immunohistochemistry and nucleic acids. Brain Pathol. 2010; 20: 1010-1020. CrossRef PubMed
20. Pulverer W, Hofner M, Preusser M, Dirnberger E, Hainfellner JA, Weinhaeusel A. A simple quantitative diagnostic alternative for MGMT DNAmethylation testing on RCL2 fixed paraffin embedded tumors using restriction coupled qPCR. Clin Neuropathol. 2013; 33: 50-60. CrossRef PubMed
21. Louis D, Ohgaki H, Wiestler O, et al. WHO Classification of Tumours of the Central Nervous System. 4th ed. 2007, Lyons, France: IARC Press.
22. Löf-Ohlin ZM, Nilsson TK. Pyrosequencing assays to study promoter CpG site methylation of the O6-MGMT, hMLH1, p14ARF, p16INK4a, RASSF1A, and APC1A genes. Oncol Rep. 2009; 21: 721-729. PubMed
23. Tuononen K, Tynninen O, Sarhadi VK, Tyybäkinoja A, Lindlöf M, Antikainen M, Näpänkangas J, Hirvonen A, Mäenpää H, Paetau A, Knuutila S. The hypermethylation of the O6-methylguanine- DNA methyltransferase gene promoter in gliomas-- correlation with array comparative genome hybridization results and IDH1 mutation. Genes Chromosomes Cancer. 2012; 51: 20-29. CrossRef PubMed
24. BerghoffAS, Stefanits H, Woehrer A, Heinzl H, Preusser M, Hainfellner JA; Vienna Comprehensive Cancer Center Central Nervous System Unit. Clinical neuropathology practice guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers. Clin Neuropathol. 2013; 32: 148-158. Cross- Ref PubMed
25. Ronaghi M, Uhlen M, and Nyren P. A sequencing method based on real-time pyrophosphate. Science. 1998; 281(5375): 363, 365.
26. Nyrén P. The history of pyrosequencing. Methods Mol Biol. 2007; 373: 1-14. PubMed
27. Ronaghi M, Karamohamed S, Pettersson B, Uhlén M, Nyrén P. Real-time DNA sequencing using detection of pyrophosphate release. Anal Biochem. 1996; 242: 84-89. CrossRef PubMed
28. Ahmadian A, Ehn M, Hober S. Pyrosequencing: history, biochemistry and future. Clin Chim Acta. 2006; 363: 83-94. CrossRef PubMed